NSE · INFINIUM · Pharmaceuticals
Infinium Pharmachem Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹158 Cr with net profit ₹8 Cr — a 5.16% net margin, versus 8.24% the period before.
Shareholding
As of 2026-03-31
- Promoter64.91%
- Public34.87%
- DII0.22%
1,061 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.5× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #1 of 30 by market cap · medians across 26 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,06,654 Cr | 274.97 | 12.31 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹27,068 Cr | 205.48 | 16.37 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹25,271 Cr | 118.83 | 13.5 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,568 Cr | 129.46 | 2.18 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,753 Cr | 67.98 | 2.42 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,715 Cr | 110.8 | 4.72 | 12.98% | 11.5% |
| Hikal Limited | ₹2,730 Cr | 189.21 | 2.28 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,264 Cr | 250.08 | 9.25 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,009 Cr | 148.95 | 6.1 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,329 Cr | 67.82 | 3.27 | 17.67% | 13.66% |
| Infinium Pharmachem Ltd.(this company) | — | 32.04 | 2.77 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashInfinium Pharmachem Ltd. operates in the Pharmaceuticals sector. The company has a market capitalisation of Rs 347 Cr. Its revenue grew by 14.8%. The company reported earnings per share (EPS) of Rs 6.43 and a return on capital employed (ROCE) of 15.64%. The debt-to-equity ratio is 0.38.
Positives
- +Revenue increased year-on-year, from Rs 71.15 Cr in Mar 2021 to Rs 157.83 Cr in Mar 2025.
- +Promoter holding is high at 64.91% as of March 31, 2026.
- +The debt-to-equity ratio is 0.38, indicating a manageable debt burden.
Negatives
- −Earnings per share (EPS) declined from Rs 8.12 in Mar 2024 to Rs 5.6 in Mar 2025.
- −Promoter holding decreased from 65.24% in Nov 2024 to 64.91% in March 2026.
- −No data is available for return on equity (ROE) or profit margin.
- −No quarterly results have been disclosed.
Financial Performance
Infinium Pharmachem Ltd. has reported annual revenues. Revenue increased from Rs 71.15 Cr in Mar 2021 to Rs 157.83 Cr in Mar 2025. Net profit also rose from Rs 2.72 Cr in Mar 2021 to Rs 8.15 Cr in Mar 2025. Earnings per share (EPS) grew from Rs 26.8 in Mar 2021 to Rs 60.07 in Mar 2022, but then decreased to Rs 5.6 in Mar 2025.
Profitability & Returns
The company's EBITDA has shown growth over the years, increasing from Rs 4.92 Cr in Mar 2021 to Rs 15.24 Cr in Mar 2025. Net profit also saw an increase, from Rs 2.72 Cr in Mar 2021 to Rs 8.15 Cr in Mar 2025. The return on capital employed (ROCE) currently stands at 15.64%.
Balance Sheet
The company maintains a debt-to-equity ratio of 0.38. The book value per share is Rs 74.27. No dividend yield information is available for Infinium Pharmachem Ltd.
Ownership & Pledges
Public shareholding is 34.87%. There are no reported pledged shares by promoters.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.